Patients experienced very mild local side effects such as rhinitis and rhinorrhea without any pulmonary dysfunction or decreased function [67]
Ian Douglas, PhD, BSc, professor of pharmacoepidemiology at the London School of Hygiene & Tropical Medicine, who was also not involved in the study, pointed out: The time at which someone starts a treatment for obesity can itself be correlated with mental health difficulties, and the effects of the medication on weight, whether this is a dramatic reduction in weight, or a disappointing lack of weight reduction, can also trigger changes in mental health. If we want to know whether GLP-1 agonists cause changes in mental health status, either through their direct pharmacological action or indirectly through their action on weight, we ideally need studies that compare people treated with GLP-1 agonists with similar people not receiving them to see if there are differences in their risk of mental health outcomes. Ian Douglas, PhD, BSc Of the NIH study, Douglas said, I wouldnt go so far as to say GLP-1 agonists prevent mental health problems based on these findings, but the results are certainly not consistent with a harm. Douglas questioned the methodology used in the new study, saying that individual spontaneous reports of suspected adverse drug reactions [] such as those used in the new study are not an appropriate resource in which to test this hypothesis about GLP-1 agonists. Ali expressed a similar concern
Cost and coverage Cost remains the largest barrier
If you struggle with any of these conditions, or struggle to lose weight on your own, ask your doctor about semaglutide injections to jumpstart your journey
